12:00 AM
 | 
Jun 12, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CEA-Cide: Phase II

Additional results from IMMU's previously reported Phase II trial of radiolabeled CEA-Cide in 30 patients who failed or were intolerant to chemotherapy showed that of 15 evaluable patients...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >